"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
IPLEX™ (mecasermin rinfabate rdna origin injection)
(mecasermin rinfabate [rDNA origin]) Injection
- Patient Information:
Details with Side Effects
IPLEX™ (mecasermin rinfabate rdna origin injection) (mecasermin rinfabate [rDNA origin] injection) is an aqueous solution for injection containing a binary protein complex of human insulin-like growth factor-1 (rhIGF-1) and human insulin-like growth factor-binding protein-3 (rhIGFBP-3), both produced by recombinant DNA technology.
rhIGF-1 and rhIGFBP-3 are produced by two separate E. coli strains: one containing the human gene for insulin-like growth factor-1 (IGF-1), the other containing the human gene for insulin-like growth factor-binding protein-3 (IGFBP-3). IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. The amino acid sequence of the rhIGF-1 protein is identical to that of endogenous human IGF-1. IGFBP-3 consists of 264 amino acid residues with a molecular weight of 28,732 daltons. The amino acid sequence of the rhIGFBP-3 protein is identical to that of endogenous human IGFBP-3. Endogenous IGFBP-3 contains 18 cysteine residues that are all paired in disulfide bonds to form the biologically active molecule, but the pairings have not been fully elucidated. The rhIGF-1 and rhIGFBP-3 proteins are complexed in a 1:1 molar ratio for formation of mecasermin rinfabate with a molecular weight of 36,381 daltons. IGFBP-3 from human plasma is glycosylated, whereas rhIGFBP-3 produced in E. coli is non-glycosylated. Glycosylated and non-glycosylated IGFBP-3 bind IGF-1 with similar affinities.
Primary structures for rhIGF-1/rhIGFBP-3:
Recombinant human insulin growth factor-1 ( rhIGF-1)
Recombinant human insulin growth factor binding protein-3 (rhIGFBP-3)
IPLEX (mecasermin rinfabate rdna origin injection) is prepared to a final concentration of 36 mg/0.6 mL in 50 mM sodium acetate and 105 mM sodium chloride with a final pH of 5.5. IPLEX (mecasermin rinfabate rdna origin injection) is for subcutaneous injection only and is a preservative-free, sterile, clear, colorless-to-slightly-yellow liquid.
Last reviewed on RxList: 3/2/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Iplex Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.